Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Cytos Makes 80% Workforce Cut and Halts All In House Programs Except Lead Allergy Drug

Firm will focus on Phase II-stage Cyt003-QbG10 candidate and continue with Pfizer and Novartis-partnered programs.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »